Anzeige
Meldung des Tages: Fundamental stark, Kurs zu niedrig – Chance beim Krebs-Impfstoff-Pionier!

Insmed Aktie News

Aktie
WKN:  A1JJA3 ISIN:  US4576693075 US-Symbol:  INSM Branche:  Biotechnologie Land:  USA
175,97 $
+5,67 $
+3,33%
151,25 € 09.01.26
Depot/Watchlist
Marktkapitalisierung *
27,47 Mrd. €
Streubesitz
-
KGV
-28,49
neu: Nachhaltigkeits-Score
45 %
Index-Zuordnung
Nasdaq 100
Weiter aufwärts? Long handeln - Jetzt mit Hebel 6,83: MM5BBR
Werbung

Insmed News

21.08.25 - PR Newswire
Insmed To Present at September Investor Conferences
Insmed To Present at September Investor Conferences PR Newswire
12.08.25 - PR Newswire
FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-​Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease PR Newswire
07.08.25 - PR Newswire
Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update
Insmed Reports Second-​Quarter 2025 Financial Results and Provides Business Update PR Newswire
04.08.25 - PR Newswire
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
Late-​Stage Pipeline Wins Boost Investor Confidence in High-​Growth Therapeutic Areas PR Newswire
04.08.25 - PR Newswire
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
Late-​Stage Pipeline Wins Boost Investor Confidence in High-​Growth Therapeutic Areas PR Newswire
24.07.25 - PR Newswire
Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025
Insmed to Host Second-​Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025 PR Newswire
11.06.25 - PR Newswire
Insmed Announces Pricing of $750 Million Public Offering of Common Stock
Insmed Announces Pricing of $750 Million Public Offering of Common Stock PR Newswire
11.06.25 - PR Newswire
Insmed Announces Proposed $650 Million Public Offering of Common Stock
Insmed Announces Proposed $650 Million Public Offering of Common Stock PR Newswire
10.06.25 - PR Newswire
Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension
Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-​Daily Therapy in Patients with Pulmonary Arterial ...
04.06.25 - PR Newswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
28.05.25 - PR Newswire
Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference
Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference PR Newswire
25.05.25 - wallstreetONLINE Redaktion
Neue Favoriten: Multimilliardär Druckenmiller tauscht Nvidia, Amazon & Tesla gegen diese High-Potential-Aktien
Top-​Investor Stanley Druckenmiller kehrt Aktien wie Nvidia, Amazon, Palantir und Tesla den Rücken, während er diese aussichtsreichen Werte aufstockt.Stanley Druckenmiller ...
21.05.25 - PR Newswire
Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study
Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study PR Newswire
08.05.25 - PR Newswire
Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update
Insmed Reports First-​Quarter 2025 Financial Results and Provides Business Update PR Newswire
29.04.25 - PR Newswire
Insmed To Present at the BofA Securities 2025 Health Care Conference
Insmed To Present at the BofA Securities 2025 Health Care Conference PR Newswire
24.04.25 - PR Newswire
Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028
Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028 PR Newswire
23.04.25 - PR Newswire
New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis
New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis PR Newswire
23.04.25 - PR Newswire
Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025
Insmed to Host First-​Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025 PR Newswire
25.03.25 - PR Newswire
Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference
Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference PR Newswire
10.03.25 - PR Newswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire

Newssuche

Videos

newspaper
09.01.26
FEIERABEND-​TRADING
Börsentäglich um 18.30 Uhr startet unser FEIERABEND-​TRADING live! René Wolfram, der Drittplatzierte ... Mehr »